Sosei Group (JSS) Stock Price & Analysis
JSS Stock Chart & Stats
- Day’s Range
- EUR 8.05 - EUR 8.05
- 52-Week Range
- EUR 4.04 - EUR 8.05
- Previous Close
- EUR 7.95
- Volume
- 0
- Average Volume (3M)
- 173
- Market Cap
- EUR 755.36M
- Enterprise Value
- EUR 149.49B
- Total Cash (Recent Filing)
- EUR 16.61B
- Total Debt (Recent Filing)
- EUR 51.96B
- Price to Earnings (P/E)
- ―
- Beta
- 0.77
- Next Earnings
- Feb 16, 2027 (Est.)
- EPS Estimate
- 0.45
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Operating Recovery
Strong revenue growth alongside a swing to operating profitability indicates improving commercial execution and operating leverage. If products and partnered programs continue contributing, the recovery can strengthen internal funding capacity and support a more durable earnings base over the next several quarters.
GPCR Discovery Platform Advantage
The breadth of Sosei’s GPCR structural data, mutations and assay results supports differentiated drug discovery capabilities. Faster hit-finding and hit-to-lead timelines can improve research productivity, expand partnering appeal, and sustain a pipeline advantage across multiple programs.
Diversified Commercial And Partnered Pipeline
Growth from marketed products provides a commercial base while partnered assets add milestone and royalty potential across several pharmaceutical relationships. This combination can diversify future revenue sources and reduce reliance on any single product or development program.
Bears Say
Net Losses And Meaningful Debt
Despite positive EBIT and improved leverage, continued net losses mean the business has not yet converted gross profitability into consistent shareholder returns. The sizable debt balance and negative ROE could constrain flexibility if operating improvements or partnership receipts weaken.
Milestone-driven Earnings Volatility
A material portion of earnings depends on external development progress and contractual milestone events rather than smooth recurring sales. This can produce uneven quarterly results, complicate planning, and make profitability less durable until commercial and royalty income becomes larger.
Uncertain Future Partnerships
Additional partnering is important to the company’s asset-light model, yet the timing, valuation and completion probability of the next transaction remain uncertain. Delays could defer upfront or milestone receipts and leave development programs dependent on existing funding and collaborations.
Sosei Group News
JSS FAQ
What was Sosei Group’s price range in the past 12 months?
What is Sosei Group’s market cap?
When is Sosei Group’s upcoming earnings report date?
How were Sosei Group’s earnings last quarter?
Is Sosei Group overvalued?
Does Sosei Group pay dividends?
What is Sosei Group’s EPS estimate?
How many shares outstanding does Sosei Group have?
What happened to Sosei Group’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Sosei Group?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Sosei Group
Nxera Pharma Co., Ltd., established in Tokyo, Japan, in 1990, is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of pharmaceutical solutions. The company's operations extend across multiple international markets, including Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its array of commercially available products encompasses respiratory treatments like Ultibro/Breezhaler and Seebri/Breezhaler for chronic obstructive pulmonary disease, as well as Enerzair and Breezhaler to manage asthma. Other marketed therapeutics include ORAVI, a unique formulation addressing oropharyngeal candidiasis, and PIVLAZ, prescribed for cerebral vasospasm. The firm boasts a robust pipeline of investigational medicines, featuring HTL0039732 for immuno-oncology, HTL0048149 for schizophrenia, Daridorexant targeting insomnia, and HTL0016878 for both schizophrenia and other neuropsychiatric conditions. Additional compounds under development include PF-07081532 for Type 2 diabetes mellitus and obesity, PF-07054894 for inflammatory bowel disease, PF-07258669 for anorexia, and PF-06954522 for metabolic disorders. The pipeline also contains NBI-1117569 for various neurological diseases and NBI-1117570 for central nervous system ailments. Furthermore, Nxera Pharma is advancing a GPR35 agonist in the preclinical stage for inflammatory bowel disease and other gastrointestinal conditions, alongside other early-stage drug candidates. The company maintains significant strategic collaborations with industry leaders such as AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christopher Cargill
- Employees
- 382
- Website
- www.nxera.life
- Address
- Midtown East, Tokyo, 107-0052, JP
Sosei Group (JSS) Earnings & Revenues
JSS Company Deck
JSS Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, driven by 27% revenue growth, a return to profitability, growth in both marketed products, substantial milestone and partnered revenue, progress across multiple clinical programs, and maintained long-term targets. The main cautions were that profitability remains subject to milestone timing, partnership transactions are not yet completed, and QUVIVIQ revenue can fluctuate because of supply timing.
View all DE:JSS earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 1 | 5 |
| Technical Analysis | 3 | 1 | 5 |
| Moving Averages | 12 | 0 | 0 |